Takeda Pharmaceutical Company Limited
TAK · NYSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $4,581,551 | $4,263,762 | $4,027,478 | $3,569,006 |
| % Growth | 7.5% | 5.9% | 12.8% | – |
| Cost of Goods Sold | $1,580,217 | $1,431,505 | $1,244,072 | $1,106,846 |
| Gross Profit | $3,001,334 | $2,832,257 | $2,783,406 | $2,462,160 |
| % Margin | 65.5% | 66.4% | 69.1% | 69% |
| R&D Expenses | $730,227 | $729,924 | $633,325 | $526,087 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,104,766 | $1,053,819 | $997,309 | $886,361 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $823,755 | $834,439 | $662,267 | $588,867 |
| Operating Expenses | $2,658,748 | $2,618,182 | $2,292,900 | $2,001,315 |
| Operating Income | $342,586 | $214,075 | $490,505 | $460,844 |
| % Margin | 7.5% | 5% | 12.2% | 12.9% |
| Other Income/Exp. Net | -$167,502 | -$161,284 | -$115,415 | -$158,273 |
| Pre-Tax Income | $175,084 | $52,791 | $375,090 | $302,571 |
| Tax Expense | $66,941 | -$91,406 | $58,052 | $72,405 |
| Net Income | $107,928 | $144,067 | $317,017 | $230,059 |
| % Margin | 2.4% | 3.4% | 7.9% | 6.4% |
| EPS | 34.17 | 46.05 | 102.15 | 73.57 |
| % Growth | -25.8% | -54.9% | 38.8% | – |
| EPS Diluted | 33.62 | 45.58 | 100.97 | 72.94 |
| Weighted Avg Shares Out | 3,211 | 3,129 | 3,104 | 3,127 |
| Weighted Avg Shares Out Dil | 3,211 | 3,161 | 3,140 | 3,154 |
| Supplemental Information | – | – | – | – |
| Interest Income | $19,638 | $78 | $5,508 | $4,591 |
| Interest Expense | $137,311 | $1,062 | $116,973 | $122,432 |
| Depreciation & Amortization | $761,396 | $644,461 | $664,400 | $583,151 |
| EBITDA | $1,210,512 | $1,143,936 | $1,284,067 | $1,183,213 |
| % Margin | 26.4% | 26.8% | 31.9% | 33.2% |